Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Product Development - KALA's lead product candidate, KPI-012, is designed to address persistent corneal epithelial defect (PCED), a rare disease related to impaired corneal healing [3] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration [3] - The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases [3] - Preclinical studies are underway to assess the MSC-S platform's potential for treating retinal degenerative diseases, including Retinitis Pigmentosa and Stargardt Disease [3] Upcoming Events - KALA management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 2:00 p.m. ET [1] - One-on-one meetings will be available on the same day [1]

Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Product Development - KALA's lead product candidate, KPI-012, is designed to address persistent corneal epithelial defect (PCED) and has received Orphan Drug and Fast Track designations from the U.S. FDA [3] - The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision [3] - Preclinical studies are underway to evaluate the MSC-S platform's potential for treating retinal degenerative diseases, including Retinitis Pigmentosa and Stargardt Disease [3] Upcoming Events - KALA management will present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025 [1] - A pre-recorded presentation will be available starting at 7:00 a.m. ET on the same day [1] - Management will participate in a panel discussion on "Novel Treatments for Front-of-the-Eye Indications" at 1:00 p.m. ET [1] - Virtual one-on-one meetings will be available throughout the conference [1]

Company Overview - KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases [3] - The company utilizes a proprietary mesenchymal stem cell secretome (MSC-S) platform for its investigational therapies [3] Product Development - KALA's lead product candidate, KPI-012, is designed to address persistent corneal epithelial defect (PCED), a rare disease related to impaired corneal healing [3] - KPI-012 has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration [3] - The company is also exploring KPI-012 for Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision [3] - Preclinical studies are underway to evaluate the MSC-S platform's potential for treating retinal degenerative diseases, including Retinitis Pigmentosa and Stargardt Disease [3] Upcoming Events - KALA management will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET [1] - One-on-one meetings will also be available on the same day [1]